Buy EYLEA Aflibercept 40mg/1ml Bayer Online
Original price was: $1,538.90.$1,208.90Current price is: $1,208.90.
EYLEA Aflibercept 40mg/1ml is an effective medication developed by Bayer for the treatment of various eye disorders. It contains aflibercept, a recombinant fusion protein that targets VEGF A and PIGF that helps curb abnormal blood vessel growth, fluid leakage, and retinal damage. Initially approved for neovascular AMD treatment in November 2011, EYLEA has proven to be highly effective, reduces dependence on photodynamic therapy, and has a low incidence of non-ocular and ocular adverse effects. Apart from neovascular AMD, it has also been approved to treat DME and RVO in which clinical trials have shown significant improvement in visual acuity. EYLEA has several advantages over other anti-VEGF therapies, including a longer treatment interval, higher binding affinity for VEGF, and better safety in specific patient subgroups.
- Description
- Reviews (9)
Description
EYLEA Aflibercept 40mg/1ml is a medication that was developed by Bayer for the treatment of several eye disorders. The active ingredient in EYLEA is aflibercept, which is a recombinant fusion protein that targets vascular endothelial growth factor (VEGF) A and PIGF (pregnancy-associated growth factor). VEGF is a protein that stimulates the growth of blood vessels, while PIGF is a protein that helps in the development of the placenta during pregnancy.
EYLEA was first approved by the US Food and Drug Administration (FDA) in November 2011 for the treatment of neovascular age-related macular degeneration (AMD). Neovascular AMD is a leading cause of blindness in people over the age of 60 and is characterized by the growth of abnormal blood vessels in the retina, leaking fluids and causing damage to the macula.
EYLEA works by blocking the action of VEGF, which promotes the growth and proliferation of abnormal blood vessels in the retina. By inhibiting VEGF, EYLEA reduces the growth of these abnormal blood vessels and reduces the fluid leakage that causes retinal damage. EYLEA is administered as an injection into the eye, usually every four to eight weeks.
EYLEA has proven to be highly effective in the treatment of neovascular AMD. In clinical trials, EYLEA has been demonstrated to significantly improve visual acuity, reduce the need for photodynamic therapy or laser photocoagulation, and maintain efficacy over a longer duration. Additionally, EYLEA has been shown to be safe and well-tolerated, with a low incidence of ocular and non-ocular adverse events compared to other anti-VEGF therapies.
EYLEA has also been approved for the treatment of diabetic macular edema (DME) and macular edema secondary to retinal vein occlusion (RVO). DME is a complication of diabetes that affects the eyes and can cause loss of vision, while RVO is a blockage in the vein that drains blood from the retina, leading to macular edema. EYLEA works in a similar way in these conditions by blocking the action of VEGF and reducing the fluid accumulation in the macula.
In clinical trials, EYLEA has demonstrated significant improvement in visual acuity and retinal thickness in patients with DME and RVO. Like in neovascular AMD, EYLEA has also been shown to have a favorable safety profile in the treatment of these conditions, with a low incidence of ocular and non-ocular adverse events.
EYLEA has several advantages over other anti-VEGF therapies such as ranibizumab (Lucentis) and bevacizumab (Avastin). EYLEA has a more extended duration of action, with a longer treatment interval than these therapies, reducing the number of visits and injections needed. EYLEA also has a higher binding affinity for VEGF than other anti-VEGF drugs, leading to a more potent and sustained effect on VEGF inhibition. Additionally, EYLEA has been shown to have a better safety profile in certain subgroups of patients, such as those with cardiovascular disease, cerebrovascular disease or those who may require anticoagulant therapy.
Overall, EYLEA Aflibercept 40mg/1ml is a highly effective and safe treatment option for neovascular AMD, DME and RVO, offering several advantages over other anti-VEGF therapies. As a result, EYLEA is becoming increasingly popular among ophthalmologists and is likely to continue to be an essential therapy for the treatment of these debilitating and potentially blinding conditions.
9 reviews for Buy EYLEA Aflibercept 40mg/1ml Bayer Online
Add a review
Related Products
Buy Xipere (triamcinolone acetonide injectable suspension) Online
Total Sales: 0
SKU: 654289
Omar Hassan –
Eylea Aflibercept exceeded my expectations in treating my eye condition. Over time, I experienced noticeable improvements in visual clarity and overall eye comfort. The medication works effectively in controlling retinal issues, and the longer dosing schedule is a big advantage. The product arrived securely packaged, and the quality feels excellent.
Keiko Tanaka –
I’ve been receiving Eylea Aflibercept injections for a while now, and the results have been consistent and reassuring. My vision has stabilized, and I’ve experienced fewer issues with blurriness. The treatment process feels well-controlled, and I haven’t had significant side effects. Packaging and handling were done professionally, ensuring safety and quality.
Daniel Weber –
Eylea Aflibercept 40mg/1ml by Bayer has been very effective in managing my retinal condition. After several treatments, I noticed clearer vision and reduced fluid buildup, which made daily activities much easier. The medication feels precise and reliable, and the longer intervals between treatments are very convenient. Everything was handled professionally, and the packaging was secure.
Ahmed Al-Farisi –
EYLEA Aflibercept by Bayer has proven very effective for my retinal vein occlusion. Over the course of treatment, I noticed better visual acuity and less fluid accumulation in my retina. The drug feels safe and well-formulated, with fewer side effects than other therapies I have tried. Packaging was secure, and everything arrived in perfect condition.
Sofia Petrova –
I’ve been using EYLEA for my diabetic macular edema, and it has exceeded my expectations. My vision clarity improved, and I’ve had far fewer episodes of blurred vision. The medication seems to target retinal issues effectively and is well-tolerated. The treatment schedule is manageable, and the entire process, from delivery to administration, was professional.
Michael Roberts –
EYLEA Aflibercept 40mg/1ml has been a game-changer for my eye health. After several treatments, I noticed significant improvement in my vision and reduced retinal swelling. The therapy feels reliable, and the longer treatment intervals are very convenient. I experienced minimal side effects, and the injections were handled professionally. Packaging and delivery were excellent.
Amina Rahman –
EYLEA Aflibercept exceeded my expectations in controlling my retinal issues. Over several months, I experienced noticeable improvements in visual acuity and reduced fluid leakage. The medication is highly effective and integrates well into a long-term treatment plan. Everything from administration to packaging was handled professionally, ensuring safety and reliability.
Lars Jönsson –
I’ve been receiving EYLEA Aflibercept injections for my macular degeneration, and the results are impressive. My vision has stabilized, and I feel more confident performing daily tasks. The therapy has fewer side effects compared to previous treatments I tried, and the longer intervals between doses are very convenient. Delivery and handling were professional and careful.
Sarah Thompson –
EYLEA Aflibercept 40mg/1ml by Bayer has been highly effective in managing my eye condition. After several treatments, I noticed improved visual clarity and reduced retinal swelling. The medication seems very precise and reliable, targeting abnormal blood vessel growth effectively. The treatment interval is convenient, and the overall experience feels safe and professional. Packaging was secure and handled carefully.